These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28194545)

  • 1. To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.
    Buer JK
    Inflammopharmacology; 2017 Apr; 25(2):185-190. PubMed ID: 28194545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A history of the term "DMARD".
    Buer JK
    Inflammopharmacology; 2015 Aug; 23(4):163-71. PubMed ID: 26002695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs].
    Pasero G; Marson P
    Reumatismo; 2011; 63(2):111-23. PubMed ID: 21776448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.
    Sanmartí R; García-Rodríguez S; Álvaro-Gracia JM; Andreu JL; Balsa A; Cáliz R; Fernández-Nebro A; Ferraz-Amaro I; Gómez-Reino JJ; González-Álvaro I; Martín-Mola E; Martínez-Taboada VM; Ortiz AM; Tornero J; Marsal S; Moreno-Muelas JV
    Reumatol Clin; 2015; 11(5):279-94. PubMed ID: 26051464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatology. Part 2: The role of medication.
    Byrne J
    Prof Nurse; 1999 Feb; 14(5):353-8. PubMed ID: 10205553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
    Simon LS
    Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DC-ART: the concept.
    Edmonds J
    J Rheumatol Suppl; 1994 Sep; 41():3-5; discussion 5-7. PubMed ID: 7799382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
    J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm maintenance therapy with disease modifying antirheumatic drugs.
    Capell H
    J Rheumatol Suppl; 2002 Nov; 66():38-43. PubMed ID: 12435167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
    Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
    Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.